Eugia Pharma Receives USFDA Approval for Daptomycin for Injection 500mg
Published: September 02, 2021
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Daptomycin for Injection 500 mg.
Indications for this product include:
- Complicated skin and skin structure infections;
- Staphylococcus aureus bloodstream infections (bacteremia) in adult patients;
- Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients.
Refer to package insert for full prescribing information.